ALX 0171

Drug Profile

ALX 0171

Alternative Names: ALX-0171; Anti-RSV nanobody; VR 465

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Class Antivirals; Proteins
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 06 Sep 2017 Ablynx intends to initiate file for a phase II trial in Respiratory syncytial virus infections (In infants) for regulatory approval in Japan in Q4 2017 and commence the trial in H1 2018
  • 21 Mar 2017 Ablynx exercises its option in the agreement with Vectura for continued development of ALX 0171 in hospitalised infants
  • 26 Sep 2016 Ablynx initiates a phase II trial for Respiratory syncytial virus infections (In infants) in Hungary and Estonia (EudraCT2016-001651-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top